Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Core Insights - Emergent BioSolutions Inc. announced a $56 million contract modification to supply ACAM2000 vaccine to the U.S. government, with total projected sales exceeding $120 million for the year [1][2][3] Group 1: Contract and Financials - The contract modification is part of an existing 10-year agreement with the Administration for Strategic Preparedness and Response (ASPR) [3] - Deliveries of the ACAM2000 vaccine are expected to begin this month, contributing to a diverse customer base [1][2] Group 2: Product Information - ACAM2000 is a single-dose vaccine approved for active immunization against smallpox and mpox for individuals at high risk [2][4] - The vaccine was first FDA approved in 2007 for smallpox and received approval for mpox in August 2024 [2] Group 3: Company Commitment - Emergent emphasizes its commitment to being a trusted partner of the U.S. government, highlighting its North American manufacturing and supply chain capabilities [2] - The company aims to strengthen public health efforts through its medical countermeasures portfolio [2][10]